Impact of special patient populations on the pharmacokinetics of echinocandins

Eline W. Muilwijk, Vincent J. C. Lempers, David M. Burger, Adilia Warris, Peter Pickkers, Rob E. Aarnoutse, Roger J. M. Bruggemann*

*Corresponding author for this work

Research output: Contribution to journalLiterature review

19 Citations (Scopus)

Abstract

Echinocandins belong to the class of antifungal agents. Currently, three echinocandin drugs are licensed for intravenous treatment of invasive fungal infections: anidulafungin, caspofungin and micafungin. While their antifungal activity overlaps, there are substantial differences in pharmacokinetics (PK). Numerous factors may account for variability in PK of echinocandins including age (pediatrics vs adults), body surface area and body composition (normal weight vs obesity), disease status (e.g., critically ill and burn patients) and organ dysfunction (kidney and liver impairment). Subsequent effects of altered exposure might impact efficacy and safety. Knowledge of PK behavior is crucial in optimal clinical utilization of echinocandin in a specific patient or patient population. This review provides up-to-date information on PK data of anidulafungin, caspofungin and micafungin in special patient populations. Patient populations addressed are neonates, children and adolescents, obese patients, patients with hepatic or renal impairment, critically ill patients (including burn patients) and patients with hematological diseases.

Original languageEnglish
Pages (from-to)799-815
Number of pages17
JournalExpert Review of Anti-infective Therapy
Volume13
Issue number6
DOIs
Publication statusPublished - 6 May 2015

Keywords

  • anidulafungin
  • caspofungin
  • critically ill
  • hematology
  • invasive fungal infection
  • micafungin
  • obesity
  • organ dysfunction
  • pediatrics
  • pharmacokinetics
  • critically-ill patients
  • stem-cell transplantation
  • extracorporeal membrane-oxygenation
  • continuous venovenous hemofiltration
  • multiple-dose pharmacokinetics
  • escmid-asterisk guideline
  • renal replacement therapy
  • liposomal amphotericin-B
  • azole antifungal drugs
  • birth-weight infants

Cite this

Muilwijk, E. W., Lempers, V. J. C., Burger, D. M., Warris, A., Pickkers, P., Aarnoutse, R. E., & Bruggemann, R. J. M. (2015). Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Review of Anti-infective Therapy, 13(6), 799-815. https://doi.org/10.1586/14787210.2015.1028366

Impact of special patient populations on the pharmacokinetics of echinocandins. / Muilwijk, Eline W.; Lempers, Vincent J. C.; Burger, David M.; Warris, Adilia; Pickkers, Peter; Aarnoutse, Rob E.; Bruggemann, Roger J. M.

In: Expert Review of Anti-infective Therapy, Vol. 13, No. 6, 06.05.2015, p. 799-815.

Research output: Contribution to journalLiterature review

Muilwijk, EW, Lempers, VJC, Burger, DM, Warris, A, Pickkers, P, Aarnoutse, RE & Bruggemann, RJM 2015, 'Impact of special patient populations on the pharmacokinetics of echinocandins', Expert Review of Anti-infective Therapy, vol. 13, no. 6, pp. 799-815. https://doi.org/10.1586/14787210.2015.1028366
Muilwijk EW, Lempers VJC, Burger DM, Warris A, Pickkers P, Aarnoutse RE et al. Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Review of Anti-infective Therapy. 2015 May 6;13(6):799-815. https://doi.org/10.1586/14787210.2015.1028366
Muilwijk, Eline W. ; Lempers, Vincent J. C. ; Burger, David M. ; Warris, Adilia ; Pickkers, Peter ; Aarnoutse, Rob E. ; Bruggemann, Roger J. M. / Impact of special patient populations on the pharmacokinetics of echinocandins. In: Expert Review of Anti-infective Therapy. 2015 ; Vol. 13, No. 6. pp. 799-815.
@article{b41b9b8548f44edb86825a45e94aca77,
title = "Impact of special patient populations on the pharmacokinetics of echinocandins",
abstract = "Echinocandins belong to the class of antifungal agents. Currently, three echinocandin drugs are licensed for intravenous treatment of invasive fungal infections: anidulafungin, caspofungin and micafungin. While their antifungal activity overlaps, there are substantial differences in pharmacokinetics (PK). Numerous factors may account for variability in PK of echinocandins including age (pediatrics vs adults), body surface area and body composition (normal weight vs obesity), disease status (e.g., critically ill and burn patients) and organ dysfunction (kidney and liver impairment). Subsequent effects of altered exposure might impact efficacy and safety. Knowledge of PK behavior is crucial in optimal clinical utilization of echinocandin in a specific patient or patient population. This review provides up-to-date information on PK data of anidulafungin, caspofungin and micafungin in special patient populations. Patient populations addressed are neonates, children and adolescents, obese patients, patients with hepatic or renal impairment, critically ill patients (including burn patients) and patients with hematological diseases.",
keywords = "anidulafungin, caspofungin, critically ill, hematology, invasive fungal infection, micafungin, obesity, organ dysfunction, pediatrics, pharmacokinetics, critically-ill patients, stem-cell transplantation, extracorporeal membrane-oxygenation, continuous venovenous hemofiltration, multiple-dose pharmacokinetics, escmid-asterisk guideline, renal replacement therapy, liposomal amphotericin-B, azole antifungal drugs, birth-weight infants",
author = "Muilwijk, {Eline W.} and Lempers, {Vincent J. C.} and Burger, {David M.} and Adilia Warris and Peter Pickkers and Aarnoutse, {Rob E.} and Bruggemann, {Roger J. M.}",
year = "2015",
month = "5",
day = "6",
doi = "10.1586/14787210.2015.1028366",
language = "English",
volume = "13",
pages = "799--815",
journal = "Expert Review of Anti-infective Therapy",
issn = "1478-7210",
publisher = "EXPERT REVIEWS",
number = "6",

}

TY - JOUR

T1 - Impact of special patient populations on the pharmacokinetics of echinocandins

AU - Muilwijk, Eline W.

AU - Lempers, Vincent J. C.

AU - Burger, David M.

AU - Warris, Adilia

AU - Pickkers, Peter

AU - Aarnoutse, Rob E.

AU - Bruggemann, Roger J. M.

PY - 2015/5/6

Y1 - 2015/5/6

N2 - Echinocandins belong to the class of antifungal agents. Currently, three echinocandin drugs are licensed for intravenous treatment of invasive fungal infections: anidulafungin, caspofungin and micafungin. While their antifungal activity overlaps, there are substantial differences in pharmacokinetics (PK). Numerous factors may account for variability in PK of echinocandins including age (pediatrics vs adults), body surface area and body composition (normal weight vs obesity), disease status (e.g., critically ill and burn patients) and organ dysfunction (kidney and liver impairment). Subsequent effects of altered exposure might impact efficacy and safety. Knowledge of PK behavior is crucial in optimal clinical utilization of echinocandin in a specific patient or patient population. This review provides up-to-date information on PK data of anidulafungin, caspofungin and micafungin in special patient populations. Patient populations addressed are neonates, children and adolescents, obese patients, patients with hepatic or renal impairment, critically ill patients (including burn patients) and patients with hematological diseases.

AB - Echinocandins belong to the class of antifungal agents. Currently, three echinocandin drugs are licensed for intravenous treatment of invasive fungal infections: anidulafungin, caspofungin and micafungin. While their antifungal activity overlaps, there are substantial differences in pharmacokinetics (PK). Numerous factors may account for variability in PK of echinocandins including age (pediatrics vs adults), body surface area and body composition (normal weight vs obesity), disease status (e.g., critically ill and burn patients) and organ dysfunction (kidney and liver impairment). Subsequent effects of altered exposure might impact efficacy and safety. Knowledge of PK behavior is crucial in optimal clinical utilization of echinocandin in a specific patient or patient population. This review provides up-to-date information on PK data of anidulafungin, caspofungin and micafungin in special patient populations. Patient populations addressed are neonates, children and adolescents, obese patients, patients with hepatic or renal impairment, critically ill patients (including burn patients) and patients with hematological diseases.

KW - anidulafungin

KW - caspofungin

KW - critically ill

KW - hematology

KW - invasive fungal infection

KW - micafungin

KW - obesity

KW - organ dysfunction

KW - pediatrics

KW - pharmacokinetics

KW - critically-ill patients

KW - stem-cell transplantation

KW - extracorporeal membrane-oxygenation

KW - continuous venovenous hemofiltration

KW - multiple-dose pharmacokinetics

KW - escmid-asterisk guideline

KW - renal replacement therapy

KW - liposomal amphotericin-B

KW - azole antifungal drugs

KW - birth-weight infants

U2 - 10.1586/14787210.2015.1028366

DO - 10.1586/14787210.2015.1028366

M3 - Literature review

VL - 13

SP - 799

EP - 815

JO - Expert Review of Anti-infective Therapy

JF - Expert Review of Anti-infective Therapy

SN - 1478-7210

IS - 6

ER -